Cagrilintide vs Retatrutide

Cagrilintide vs Retatrutide is a choice between a non-GLP-1 satiety signal and a three-receptor metabolic drug. Cagrilintide fits the amylin-first goal; retatrutide has produced the larger monotherapy weight-loss averages. No trial has compared them directly, and no human trial has tested them together, so neither earns a universal crown.

What is the core difference?

Cagrilintide and retatrutide work on different receptor systems. Cagrilintide activates amylin receptors, which are formed when the calcitonin receptor pairs with receptor activity-modifying proteins (RAMPs), as well as the calcitonin receptor itself. Retatrutide activates GLP-1, GIP, and glucagon receptors. In plain English: this is amylin vs triple agonist, not two versions of the same GLP-1 drug.

Cagrilintide copies a hormone released with insulin after eating. The signal slows stomach emptying and tells the brainstem that a meal has done its job. Our guide to what an amylin analogue is explains that pathway without requiring a pharmacology decoder ring. Structural research has directly mapped cagrilintide at the AMY1, AMY2, AMY3, and calcitonin receptors (PubMed).

Retatrutide wires three switches into one molecule. GLP-1 and GIP contribute appetite and glucose effects; glucagon is intended to add energy-expenditure and liver-fat effects. The receptor lists do not overlap. The downstream experiences and side effects can still overlap because both compounds reduce food intake and commonly cause gastrointestinal symptoms.

Which compound produced more weight loss?

Retatrutide produced the larger monotherapy average, but the numbers are not a direct race. In cagrilintide’s 26-week Phase 2 dose-finding trial, the 4.5 mg group lost 10.8% of body weight on average under the trial-product analysis, versus 3.0% with placebo. In retatrutide’s 48-week Phase 2 trial, the 12 mg group lost 24.2%, versus 2.1% with placebo.

That makes retatrutide the evidence-based pick when the goal is magnitude. It does not prove that the same person would lose exactly twice as much. The cagrilintide trial ran for 26 weeks; the retatrutide trial ran for 48. Entry criteria, dose escalation, participants, and statistical handling differed. Calling those results “head-to-head” would turn two good trials into one bad comparison.

Retatrutide now also has sponsor-reported Phase 3 results. Lilly reported 28.3% mean weight loss with 12 mg at 80 weeks in TRIUMPH-1, versus 2.2% with placebo. That figure is newer than the peer-reviewed Phase 2 paper; Lilly stated that fuller results would follow in medical presentations and a peer-reviewed publication. Cagrilintide weight loss monotherapy is also in Phase 3 development, but it has no completed cagrilintide-versus-retatrutide trial. The shared badge here therefore means both have human randomized evidence, not that they have been randomized against each other. See how evidence tiers work.

Does a cagrilintide retatrutide stack make sense?

The cagrilintide retatrutide stack has a tidy biological rationale and no human trial behind it. Cagrilintide adds an amylin/calcitonin-family signal without duplicating retatrutide’s GLP-1, GIP, or glucagon targets. That non-overlap is exactly why community discussions and peptide sellers combine them. Receptor coverage, however, is a hypothesis about benefit—not a safety study, dose-finding study, or proof of extra weight loss.

No registered or published human trial was found for the combination in searches of ClinicalTrials.gov and PubMed reviewed on July 16, 2026. Cagrilintide does have human combination data with semaglutide as CagriSema. Retatrutide plus cagrilintide is a different four-pathway experiment and cannot borrow CagriSema’s evidence.

The live search results make the distinction easy to miss: several pages sell a blend or lead into a protocol. Molecular Reference sells neither compound. FDA’s current language is also unusually direct: retatrutide and cagrilintide are not FDA-approved components and cannot be used in compounding under federal law. A premixed vial on a storefront is not a clinical formulation wearing casual clothes.

Do appetite feel and side effects differ?

Cagrilintide is often described as reducing hunger drive and bringing fullness earlier, while retatrutide reports sometimes describe food as less appealing or even aversive. Those descriptions are not a validated trial scale and were never compared head-to-head. They belong in the “reported experience” column, not the efficacy column. Satiety quality remains a useful question that current research has not settled.

Both compounds commonly produce nausea, vomiting, diarrhea, and constipation, especially during dose escalation. Retatrutide’s Phase 2 trial also found dose-dependent heart-rate increases that peaked around week 24 and later declined. Combining two appetite-reducing investigational drugs could intensify shared gastrointestinal effects, but no human combination study has measured how often or how severely. That uncertainty is the stack’s central safety fact.

As of July 2026, both compounds remain investigational in the United States. Neither has an FDA-approved indication, and both fall under WADA’s S0 category for non-approved substances, prohibited at all times in tested sport. The site’s dated regulatory-status guide explains why “research use only” is not a pharmacy approval category.

Which one fits which goal?

Cagrilintide fits the goal of studying appetite through a non-GLP-1, non-GIP, non-glucagon pathway; retatrutide fits the goal of the largest reported monotherapy weight-loss magnitude. The reverse-order search, retatrutide vs cagrilintide, reaches the same answer: the goal chooses the compound. The structured picks above are lanes, not a podium.

Choose the cagrilintide column when the defining question is amylin-based satiety or avoiding retatrutide’s GIP and glucagon receptor arms. Choose the retatrutide column when the defining question is trial magnitude or having reported pivotal Phase 3 monotherapy results. Choose neither column for the claim that a combined blend is human-tested; that evidence does not exist yet.

The cleanest cagrilintide vs retatrutide reading is encouraging without pretending the science has already answered everything. Both compounds moved well beyond animal-only evidence. Retatrutide has the larger separate-trial numbers. Cagrilintide opens a distinct satiety pathway. The direct comparison—and especially the combination study—remains work for a trial, not a vendor’s product page. Browse the wider comparison library for matchups with actual head-to-head data clearly marked.